ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.
The phase 3 trial of the nasal spray in Japanese patients aged 6 to 17, who had anaphylactic symptoms after food, had a 100% success rate in removing symptoms in about 16 minutes, the company said Thursday in a statement.
Additional tests in China matched US studies with similar results, the company said.
The treatment is approved in the US for severe allergic reactions.
Price: 12.50, Change: +0.23, Percent Change: +1.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。